Darya Alizadeh
Research Subjects
Darya Alizadeh has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Christine E. Brown
Department of Hematology & Hematopoietic Cell Transplantation (T Cell Therapeutics Research Laboratories), City of Hope Beckman Research Institute and Medical Center, Duarte, CA 91010, USA
11 shared publications - Brenda Aguilar
City of Hope 1 Department of Hematology and Hematopoietic Cell Transplantation Duarte, California
10 shared publications - Julie R. Ostberg
City of Hope 1 Department of Hematology and Hematopoietic Cell Transplantation Duarte, California
10 shared publications - Renate Starr
T Cell Therapeutics Research Labs, Cellular Immunotherapy Center, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California
10 shared publications - Stephen J. Forman
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, USA
10 shared publications - Wen-Chung Chang
City of Hope 1 Department of Hematology and Hematopoietic Cell Transplantation Duarte, California
10 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S1| Amino acid substitution for meCAR design and affinity characterization of meCAR variants.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S1| Amino acid substitution for meCAR design and affinity characterization of meCAR variants.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Data from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Chimeric antigen receptor (CAR) T cells have transformed cancer treatment, yet challenges for achieving broader clinical success remain, including overcoming tumor antigen heterogeneity and limited T-cell fitness. To address these challenges and enhance CAR T-cell functionality, we leveraged meditope technology, a lock-and-key platform where fragment antigen-binding (Fab) regions of antibodies are modified to bind a small cyclic peptide termed meditope peptide (meP). We developed a panel of meditope-enabled Fab-based CARs (meCAR), which showed selective binding to the meP and comparable activity with traditional single-chain variable fragment–based CARs. Focusing on HER2-targeted meCARs for evaluating platform utility, we exploited the modularity of the meditope platform to detect meCAR T cells using meP-fused fluorescent agents, promote meCAR T-cell expansion via meP-fused IL15 cytokine, and broaden tumor antigen targeting through meP-fused antibodies to address tumor heterogeneity. These findings establish the meditope technology as a versatile strategy to augment CAR T-cell functionality and overcome key limitations of current CAR-based therapies.See related Spotlight, p. 1536
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Chimeric antigen receptor (CAR) T cells have transformed cancer treatment, yet challenges for achieving broader clinical success remain, including overcoming tumor antigen heterogeneity and limited T-cell fitness. To address these challenges and enhance CAR T-cell functionality, we leveraged meditope technology, a lock-and-key platform where fragment antigen-binding (Fab) regions of antibodies are modified to bind a small cyclic peptide termed meditope peptide (meP). We developed a panel of meditope-enabled Fab-based CARs (meCAR), which showed selective binding to the meP and comparable activity with traditional single-chain variable fragment–based CARs. Focusing on HER2-targeted meCARs for evaluating platform utility, we exploited the modularity of the meditope platform to detect meCAR T cells using meP-fused fluorescent agents, promote meCAR T-cell expansion via meP-fused IL15 cytokine, and broaden tumor antigen targeting through meP-fused antibodies to address tumor heterogeneity. These findings establish the meditope technology as a versatile strategy to augment CAR T-cell functionality and overcome key limitations of current CAR-based therapies.See related Spotlight, p. 1536
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S5| Binding of meP-αCD20 on tumor triggers dual-targeting of HER2 meCAR T cells.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S5| Binding of meP-αCD20 on tumor triggers dual-targeting of HER2 meCAR T cells.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S6| Dual-targeting of HER2-meCAR T cells by meP-αPD-L1 and meP-αCD20.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S6| Dual-targeting of HER2-meCAR T cells by meP-αPD-L1 and meP-αCD20.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S7| Optimized meP-αCD20 Fab shows improved antitumor activity.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S7| Optimized meP-αCD20 Fab shows improved antitumor activity.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig.S4| meP-IL15s-mediated enrichment of meCAR T cells and assessment of toxicity.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig.S4| meP-IL15s-mediated enrichment of meCAR T cells and assessment of toxicity.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S3| Design and characterization of meditope-enabled CARs targeting additional antigens.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S3| Design and characterization of meditope-enabled CARs targeting additional antigens.
- Open Access
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S2| in vivo efficacy of HER2 meCAR T cells in an OVCAR-3 xenograft model.
- 5 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Supplementary Fig. S2| in vivo efficacy of HER2 meCAR T cells in an OVCAR-3 xenograft model.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (10) , 1553-1569
Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Chimeric antigen receptor (CAR) T cells have transformed cancer treatment, yet challenges for achieving broader clinical success remain, including overcoming tumor antigen heterogeneity and limited T-cell fitness. To address these challenges and enhance CAR T-cell functionality, we leveraged meditope technology, a lock-and-key platform where fragment antigen-binding (Fab) regions of antibodies are modified to bind a small cyclic peptide termed meditope peptide (meP). We developed a panel of meditope-enabled Fab-based CARs (meCAR), which showed selective binding to the meP and comparable activity with traditional single-chain variable fragment–based CARs. Focusing on HER2-targeted meCARs for evaluating platform utility, we exploited the modularity of the meditope platform to detect meCAR T cells using meP-fused fluorescent agents, promote meCAR T-cell expansion via meP-fused IL15 cytokine, and broaden tumor antigen targeting through meP-fused antibodies to address tumor heterogeneity. These findings establish the meditope technology as a versatile strategy to augment CAR T-cell functionality and overcome key limitations of current CAR-based therapies. See related Spotlight, p. 1536
- 4 August 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (10) , 1553-1569
Open AccessMeditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells
Chimeric antigen receptor (CAR) T cells have transformed cancer treatment, yet challenges for achieving broader clinical success remain, including overcoming tumor antigen heterogeneity and limited T-cell fitness. To address these challenges and enhance CAR T-cell functionality, we leveraged meditope technology, a lock-and-key platform where fragment antigen-binding (Fab) regions of antibodies are modified to bind a small cyclic peptide termed meditope peptide (meP). We developed a panel of meditope-enabled Fab-based CARs (meCAR), which showed selective binding to the meP and comparable activity with traditional single-chain variable fragment–based CARs. Focusing on HER2-targeted meCARs for evaluating platform utility, we exploited the modularity of the meditope platform to detect meCAR T cells using meP-fused fluorescent agents, promote meCAR T-cell expansion via meP-fused IL15 cytokine, and broaden tumor antigen targeting through meP-fused antibodies to address tumor heterogeneity. These findings establish the meditope technology as a versatile strategy to augment CAR T-cell functionality and overcome key limitations of current CAR-based therapies. See related Spotlight, p. 1536
- 5 July 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (17) , 2813-2815
Uncovering the Role of CD4+ CAR T Cells in Cancer Immunotherapy
Chimeric antigen receptor (CAR) T-cell therapy has transformed clinical care against blood malignancies and is seeing encouraging progress against solid tumors. While scientific advancement has been rapid, our mechanistic understanding of intrinsic features of CAR-engineered T cells is still evolving. CAR products typically consist of CD4+ and CD8+ T-cell subsets at variable ratios, yet a clear understanding of how each subset contributes together and independently to therapeutic response is lacking. CD8+ CAR T cells are well characterized for their perforin-dependent killing effects; however, the role of CD4+ CAR T cells as “helpers” versus “killers” has been variable across models and warrants more in-depth investigation. A recent study by Boulch and colleagues published in Nature Cancer demonstrates that CD4+ CAR T cells, alone, can exert potent antitumor activity through a mechanism involving IFNγ. CD4+ CAR T-cell production of IFNγ creates a cytokine field that can act at a distance to kill both antigen-positive and -negative tumor cells that are sensitive to the proapoptotic effects of IFNγ. These new findings reveal important insights for the antitumor effects mediated by CD4+ CAR T cells, which could have significant clinical implications.
- 5 July 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (17) , 2813-2815
Uncovering the Role of CD4+ CAR T Cells in Cancer Immunotherapy
Chimeric antigen receptor (CAR) T-cell therapy has transformed clinical care against blood malignancies and is seeing encouraging progress against solid tumors. While scientific advancement has been rapid, our mechanistic understanding of intrinsic features of CAR-engineered T cells is still evolving. CAR products typically consist of CD4+ and CD8+ T-cell subsets at variable ratios, yet a clear understanding of how each subset contributes together and independently to therapeutic response is lacking. CD8+ CAR T cells are well characterized for their perforin-dependent killing effects; however, the role of CD4+ CAR T cells as “helpers” versus “killers” has been variable across models and warrants more in-depth investigation. A recent study by Boulch and colleagues published in Nature Cancer demonstrates that CD4+ CAR T cells, alone, can exert potent antitumor activity through a mechanism involving IFNγ. CD4+ CAR T-cell production of IFNγ creates a cytokine field that can act at a distance to kill both antigen-positive and -negative tumor cells that are sensitive to the proapoptotic effects of IFNγ. These new findings reveal important insights for the antitumor effects mediated by CD4+ CAR T cells, which could have significant clinical implications.